Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2014 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Reports Data and Safety Monitoring Board Recommendation to Continue ixCELL-DCM Clinical Trial

ANN ARBOR, Mich., April 9, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
April 01, 2014 08:30 ET | Source: Aastrom Biosciences, Inc.

Aastrom Announces Appointments of Dr. Ross Tubo as Chief Scientific Officer and Dr. David Recker as Chief Medical Officer

ANN ARBOR, Mich., April 1, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
March 19, 2014 09:02 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences to Present at the 2014 Regen Med Investor Day

ANN ARBOR, Mich., March 19, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
March 13, 2014 16:05 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports Fourth-Quarter and Year-End 2013 Financial Results

ANN ARBOR, Mich., March 13, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
March 06, 2014 16:05 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences to Host Fourth Quarter 2013 Investor Call on March 13, 2014

ANN ARBOR, Mich., March 6, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
January 27, 2014 16:05 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Enters Into $15 Million Equity Commitment With Lincoln Park Capital

ANN ARBOR, Mich., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
December 19, 2013 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia

ANN ARBOR, Mich., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
November 15, 2013 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Regains Compliance With NASDAQ Equity Standard Listing Requirement

ANN ARBOR, Mich., Nov. 15, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
November 12, 2013 16:05 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences Reports Third-Quarter and Nine-Month 2013 Financial Results

ANN ARBOR, Mich., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
November 12, 2013 09:00 ET | Source: Aastrom Biosciences, Inc.

Aastrom Biosciences to Present at the 2013 Therapeutic Area Partnerships Conference

ANN ARBOR, Mich., Nov. 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...